key: cord-0740365-0wd4tgcb
authors: Scheler, Carlos A.; Discacciati, Michelle G.; Vale, Diama B.; Lajos, Giuliane J.; Surita, Fernanda; Teixeira, Julio C.
title: Mortality in pregnancy and the postpartum period in women with severe acute respiratory distress syndrome related to COVID‐19 in Brazil, 2020
date: 2021-07-16
journal: Int J Gynaecol Obstet
DOI: 10.1002/ijgo.13804
sha: 7dac485aa5d0f7f0acd6ee1562e54645bbde0a5b
doc_id: 740365
cord_uid: 0wd4tgcb

OBJECTIVE: To estimate fatality rates due to severe acute respiratory distress syndrome (ARDS) related to COVID‐19 in Brazilian women, comparing pregnant and postpartum women with nonpregnant women. METHODS: A cross‐sectional study of 12 566 pregnant and postpartum women (obstetric group) and 90 025 nonpregnant women (nonobstetric group) aged 15–49 years reported with severe ARDS in 2020. The Brazilian ARDS Surveillance System was used to compare the outcome (death or cure) between the groups, considering age, race, or comorbidities. RESULTS: The mortality rate related to ARDS/COVID‐19 in the obstetric group was 7.8% (377/4853) compared with 13.9% (5946/42 915) in the nonobstetric group. Comorbidity was associated with increased fatality cases for both groups, but higher in the nonobstetric group (22.8% vs 13.3%). In the obstetric group, deaths related to COVID‐19 were concentrated in the third trimester or postpartum period. If comorbidity was present, deaths by COVID‐19 were 4.4 times higher than ARDS due to other etiologies, and twice higher in women who self‐reported as black (13.7%) than white women (6.7%). Considering ADRS etiology, deaths by COVID‐19 were 3.4–6.7 times higher than any other etiology. CONCLUSION: ARDS related to COVID‐19 in obstetric patients was an important factor for worse clinical outcomes, with 3–6 times higher death rates than other ARDS etiologies. Pregnant and postpartum women with severe ARDS related to COVID‐19 had a lower fatality rate than nonpregnant women, even with associated comorbidity.

The coronavirus disease pandemic is a critical issue for global health and it has had a massive impact on all world regions.

At the beginning of the pandemic, a major concern among clinicians was whether pregnant women would represent a group at risk for serious outcomes, as previously seen for acute respiratory distress syndrome (ARDS) caused by the influenza virus. 1, 2 New scientific information is continuously being collected. In July 2020, Takemoto et al. 3 (SARS-CoV-2). [4] [5] [6] In a recent study, Lokken et al. 7 reported a COVID-19 case fatality rate in pregnant patients 13.6-fold higher than nonpregnant women of a similar age in Washington State, USA. However, current data indicate that pregnant and postpartum women do not appear to represent a risk group for worse outcomes due to COVID-19 and the literature shows a wide range of mortality rates for this group, ranging from 0 to 11. [7] [8] [9] [10] We are constantly monitoring the ARDS national surveillance system in Brazil to assess the correlation of ARDS and deaths due to COVID-19 in pregnant and postpartum women. The aim of the present study was to evaluate death rates in 2020 due to severe ARDS in pregnant and postpartum women compared with nonpregnant women in Brazil, taking etiology into consideration (i.e. diagnosis of COVID-19 or other respiratory etiologies).

A cross-sectional study was performed using data for the year 2020 from the Brazilian Acute Respiratory Distress Syndrome Surveillance System (Sivep-Gripe), which is the official system for recording cases and deaths due to ARDS in Brazil. The information used herein was gathered since the onset of the COVID-19 pandemic. Aggregate data are available online for public and technical consultations. 11 A secondary databank containing information for women aged 15-49 years with severe ARDS was built from the national database, which was then divided into two groups: an obstetric group comprising pregnant women and women in the postpartum period (up to 45 days after delivery) and a nonobstetric group comprising nonpregnant women.

National surveillance rules require compulsory notification of all severe ARDS cases from all healthcare units in Brazil, public or private, according to the Brazilian Ministry of Health regulatory guidelines. 12 The notification information is entered locally into the Sivep-Gripe by trained healthcare professionals, who fill out a predefined form through a web platform. The informatics system and the notification rules were established in 2009, during the H1N1 pandemic. Once pregnant women were identified as a relevant H1N1 risk group, specific fields related to pregnancy and the postpartum period were incorporated into the form at that time. 13 The criteria required to define an ARDS case consists of two or more of the following symptoms: fever, chills, sore throat, headache, cough, coryza, olfactory or taste disorders AND acute respiratory condition (dyspnea, respiratory distress OR persistent chest discomfort, oppression OR oxygen saturation less than 95% in room air OR bluish coloration of the lips or face). 11 Inclusion criteria in the present study were all severe ARDS cases in women aged 15-49 years notified between the eighth epidemi- The filters applied were sex, age at diagnosis, and pregnancy period (first, second, or third trimester or postpartum period). Other analyzed variables were: race self-reported as white, black, brown, yellow (skin color), or indigenous (ethnicity), and associated comorbidities. A detailed definition of the variables and categories is available in the original surveillance recording system. 11

All information on comorbidities recorded in the obstetric group were reviewed in detail and, in the case of more than one reported comorbidity, one was considered to be the most relevant. This main comorbidity was defined by the authors according to the following predefined order of clinical relevance: chronic respiratory disease (including asthma), cardiovascular disease, diabetes, pregestational obesity (body mass index [BMI, calculated as weight in kilograms divided by the square of height in meters] >30), and other (immune deficiency, hematologic disease, hepatopathy, genetic syndrome, chronic kidney pathology, neurology disorder, cancer, rheumatologic disease, drug addiction or trauma).

The primary outcome analyzed was the evolution of the disease, categorized as cure or death. We also conducted an exploratory analysis calculating an estimated specific mortality rate due to ARDS related to COVID-19 in the obstetric group. The ratio between the number of these deaths obtained in the Sivep-Gripe database and the female population aged 15-49 years according to the Brazilian official projections for 2020 was determined. 14 We also estimated a maternal mortality rate as a ratio between the number of deaths due to ARDS related to 

Severe ARDS was reported in a total of 102 591 women aged 15- Table 2 provides a detailed analysis of the proportion of deaths by etiology and presence of comorbidity for the obstetric and nonobstetric groups. All findings were statistically significant (P < 0.001), with the exception of the "COVID-19 ARDS" group without comorbidity and the "Other ARDS" group with comorbidity. The obstetric group had a lower proportion of deaths related to COVID-19 than the nonobstetric group (7.8% vs 13.9%; OR 0.52; 95% CI, 0.47-0.58) and this difference was more evident in women with comorbidity (13.3% for the obstetric group vs 22.8% for nonobstetric group; OR 0.52; 95% CI, 0.44-0.61). If no comorbidity was reported, this inference is still valid, although the proportions are more similar between the groups (5.5% for the obstetric group vs 6.6% for the nonobstetric group). When the etiology of severe ARDS was considered in the obstetric group, death rate related to COVID-19 was 7.8% compared with 2.4% for other etiologies (OR 3.43; 95% CI, 2.83-4.17). Notably, in the cases without comorbidity, the outcome of death related to COVID-19 had an increased OR of 6.76 (95% CI, 6.41-7.52). In a similar analysis for the nonobstetric group, death related to COVID-19 remained twice more frequent as death related to other etiologies (OR 1.97; 95% CI, 1.88-2.07) and this association became more evident in women with comorbidity (OR 6.94; 95% CI, 6.41-7.52). diagnosis in severe ARDS appears to have lower case fatality outcomes. In our study, severe ARDS related to COVID-19 in obstetric women had a 7.8% fatality rate, which was lower than in nonpregnant women aged 15-49 years (13.9%). The association with comorbidity worsened the fatality rate in both groups, more evidently in the nonobstetric group (22.8% vs 13.3% for the obstetric group).

Considering the women without comorbidity, this fatality association persists, although with a more similar proportion between the groups (6.6% for the nonobstetric group vs 5.5% for the obstetric group). Moreover, comorbidities in the obstetric group were related to 50% of the deaths, but there was no difference concerning the onset of comorbidity before or during the pregnancy, or even to the types of comorbidities considered. Of course, the presence of more than one comorbidity was related to a worse prognosis.

The study by Lokken et al. 7 of 240 pregnant women reported 24 (10%) cases requiring hospitalization and three fatal outcomes (12.5%); it concluded that pregnant patients had a 13.6-fold higher case fatality rate than nonpregnant women. Although the present study had contrasting results with a lower fatality rate among women from the obstetric group (7.8%), only women who were pregnant or in the postpartum period with severe ARDS related to COVID-19

were considered, which represents a more restricted group with a worse prognosis; furthermore, we analyzed a more expressive number of cases with 377 deaths.

In another Brazilian study published in July 2020, preliminary results showed 124 deaths among 978 pregnant women with severe disease related to COVID-19 (12.7% fatality). 3, 5 Such information also came from the Sivep-Gripe databank; however, comparatively, our study computed considerably more data from an extended period, thus attributing relatively higher relevance to the evidence pre- Looking at our findings regarding race and ethnicity in the obstetric group, we found that the proportion of deaths was higher in black women, followed by brown, white, and indigenous women.

Black women had the worst mortality rate (13.6%), which was twice as high as white women (6.7% [19] [20] [21] As reported in the present study, severe cases and deaths among pregnant women occurred mainly in certain social strata and patients with comorbidities. We demonstrated that severe ARDS In conclusion, COVID-19 was an important factor for worse clinical outcomes in Brazilian pregnant and postpartum women with a 3.4-times higher death rate than other ARDS etiologies. In 2020, severe ARDS related to COVID-19 in obstetric patients had a 7.8% fatality rate, an alarming but lower rate than in nonpregnant women (13.9%).

The authors have no conflicts of interest.

CS, MD, and JT: study design, planning and conduct, data analysis, and manuscript writing. DV and FS: study design, data analysis, and manuscript writing. GL: data analysis and manuscript writing.

Julio C. Teixeira https://orcid.org/0000-0002-0979-376X

Severe maternal morbidity due to respiratory disease and impact of 2009 H1N1 influenza A pandemic in Brazil: results from a national multicenter cross-sectional study

The burden of indirect causes of maternal morbidity and mortality in the process of obstetric transition: a cross-sectional multicenter study

The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting

Maternal mortality and COVID-19

Clinical characteristics and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis

Risk factors for adverse outcomes among pregnant and postpartum women with acute respiratory distress syndrome due to COVID-19 in Brazil

Disease severity, pregnancy outcomes, and maternal deaths among pregnant patients with severe acute respiratory syndrome coronavirus 2 infection in Washington State

Coronavirus disease 2019 during pregnancy: do not underestimate the risk of maternal adverse outcomes

Maternal and perinatal outcomes related to COVID-19 and pregnancy: overview of systematic reviews

Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection

SIVEP-GRIPE (Influenza Epidemiological Information and Surveillance System)

Information System for Notifiable Diseases

In: Health Surveillance Secretariat. Guide to Health Surveillance

Institute of Geography and Statistics: The projection of the Brazilian population for 2020

Accessed February 2, 2021. 16. National Health Council. Brazil: RESOLUTION 510

Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza a respiratory viruses

World Health Organization: Epidemiological Update: Coronavirus Disease (COVID-19)

Pregnancy, postpartum care, and COVID-19 vaccination in 2021

Inclusion of pregnant individuals among priority populations for COVID-19 vaccination for all 50 US States

Coronavirus disease 2019 (COVID-19) vaccines and pregnancy: what obstetricians need to know

Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data

Mortality in pregnancy and the postpartum period in women with severe acute respiratory distress syndrome related to COVID-19 in Brazil, 2020